Skip to main content
All lobbying filings

INDEPENDENT PHARMACY COOPERATIVE

Lobbying for INDEPENDENT PHARMACY COOPERATIVE · National GPO and drug distribution services for independent pharmacies.

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 8, 2026
Expenses
$30,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Wisconsin

Official filing document

 Government bodies contacted 6

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 1

IPC supports S. 526 Pharmacy Benefit Manager Transparency Act of 2025 IPC supports S. 527 "Prescription Pricing for People Act of 2025 IPC supports H.R. 4317/S.3345 PBM Reform Act of 2025 IPC supports H.R. 3164/S. 2426 - "Main Street Pharmacy Access Act" IPC supports H.R. 6609 & H.R. 6610 - Pharmacists Fights Back Act IPC supports H.R. 5256 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act (340B ACCESS Act) IPC monitors Trump Administration 340B Rebate Pilot Program adoption and implementation IPC supports OBBBA - Rural Health Transformation Program - grant implementation IPC monitors Senate BI-Partisan 340B working group - draft legislation IPC monitors Trump Administration overseas manufactured drug Section 232 tariffs investigation IPC monitors Trump Administration Drug Pricing Most Favored Nations status/Direct to Consumer (DTC) prescription drug distribution proposals IPC monitors HR 879/S.3794 Safe Drug Act of 2026 IPC is opposed to the HRSA 340B proposed rebate model IPC opposes HR 6509/S. 3794 Safe Drug Act of 2026. IPC opposes HR 5316 the "Drug Shortage Compounding Patient Access Act of 2025" IPC supports the Breakup Big Medicine Act S. 3822 IPC supports Protecting Pharmacies in Medicaid Act S. 927 IPC supports the US Department of Labor proposed rule on PBM transparency [RIN 1210-AB37]

 Bills named in this filing 15
  • S. 526
    Pharmacy Benefit Manager Transparency Act of 2025
  • S. 527
    Prescription Pricing for the People Act of 2025
  • H.R. 4317
    PBM Reform Act of 2025
  • S. 3345
    PBM Price Transparency and Accountability Act
  • H.R. 3164
    Ensuring Community Access to Pharmacist Services Act
  • S. 2426
    Equitable Community Access to Pharmacist Services Act
  • H.R. 6609
    Pharmacists Fight Back in Medicare and Medicaid Act
  • H.R. 6610
    Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]
  • H.R. 5256
    340B ACCESS Act
  • H.R. 879
    Medicare Patient Access and Practice Stabilization Act of 2025
  • S. 3794
    SAFE Drugs Act of 2026
  • H.R. 6509
    SAFE Drugs Act of 2025
  • H.R. 5316
    Drug Shortage Compounding Patient Access Act of 2025
  • S. 3822
    Break Up Big Medicine Act
  • S. 927
    Protecting Pharmacies in Medicaid Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem